Published in J Pharm Sci on July 01, 1966
Characterizing non-constant relative potency. Regul Toxicol Pharmacol (2011) 0.86
Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol (1992) 4.39
Tracking of blood lipids and blood pressures in school age children: the Muscatine study. Circulation (1978) 3.59
Predictors of good function: the Framingham Study. J Chronic Dis (1987) 2.02
Coronary heart disease risk factors in school children: the Muscatine study. J Pediatr (1975) 2.02
Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. N Engl J Med (1999) 2.00
Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study. J Chronic Dis (1987) 1.86
Low drug attributability of aplastic anemia in Thailand. The Aplastic Anemia Study Group. Blood (1997) 1.55
Knowledge about AIDS and high-risk behavior among intravenous drug users in New York City. AIDS (1987) 1.47
Short course training in epidemiology and biostatistics for graduate and undergraduate public health professionals. Public Health Rep (1994) 1.40
Progress in the battle against hypertension. Changes in blood pressure levels in the United States from 1960 to 1980. Hypertension (1987) 1.35
Trends in total mortality and mortality from heart disease in 26 countries from 1950 to 1978. Int J Epidemiol (1985) 1.26
Preliminary studies of an acid-labile factor (ALF) in human sera that inactivates platelet-activating factor (PAF). Clin Immunol Immunopathol (1980) 1.22
A noninvasive technique for measurement of changes in specific airway resistance. J Appl Physiol Respir Environ Exerc Physiol (1979) 1.21
Evaluation of impedance cardiac output in children. Pediatrics (1971) 1.19
Coronary heart disease mortality rates in United States blacks, 1968-1978: interstate variation. Am Heart J (1984) 1.19
Human serum acid-labile factor is an acylhydrolase that inactivates platelet-activating factor. Fed Proc (1983) 1.16
Blood pressure in adolescence. The United States Health Examination survey. Hypertension (1980) 1.12
The first derivative thoracic impedance cardiogram. Circulation (1970) 1.11
Identification of sentinel health events as indicators of environmental contamination. Environ Health Perspect (1991) 1.10
Incidence of aplastic anemia in Bangkok. The Aplastic Anemia Study Group. Blood (1991) 1.07
Blood pressure in childhood. The National Health Examination Survey. Hypertension (1980) 1.06
A longitudinal study of body fatness in childhood and adolescence. J Pediatr (1979) 1.04
An association of aplastic anaemia in Thailand with low socioeconomic status. Aplastic Anemia Study Group. Br J Haematol (1995) 1.00
The effects of triiodothyronine on hemodynamic responses to epinephrine and norepinephrine in man. J Pharmacol Exp Ther (1967) 0.93
Scientific and ethical issues in the use of placebo controls in clinical trials. Annu Rev Public Health (1994) 0.90
Substrate specificity and partial characterization of the PAF-acylhydrolase in human serum that rapidly inactivates platelet-activating factor. J Immunol (1986) 0.90
Site specific osteoarthritis and the index to ring finger length ratio. Osteoarthritis Cartilage (2009) 0.89
Regional patterns in the incidence of aplastic anemia in Thailand. The Aplastic Anemia Study Group. Am J Hematol (1999) 0.89
Sentinel event strategies in environmental health. Annu Rev Public Health (1993) 0.88
Secondary sex characteristics of boys 12 to 17 years of age: the U.S. Health Examination Survey. J Pediatr (1979) 0.85
Agranulocytosis in Bangkok, Thailand: a predominantly drug-induced disease with an unusually low incidence. Aplastic Anemia Study Group. Am J Trop Med Hyg (1999) 0.84
VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF). Peptides (1984) 0.84
Physical activity as a risk factor for osteoarthritis of the knee. Ann Epidemiol (1994) 0.83
Study of some factors contributing to aerosol production by the air-turbine handpiece. J Dent Res (1969) 0.82
Body mass index growth in a sample of U.S. children: repeated measures data analysis of the Minneapolis Children's Blood Pressure Study. Am J Hum Biol (2001) 0.81
The presence of platelet-activating factor (PAF) in normal human mixed saliva. J Immunol (1981) 0.81
Use of household pesticides and the risk of aplastic anaemia in Thailand. The Aplastic Anemia Study Group. Int J Epidemiol (1997) 0.80
Ruby laser photocoagulation therapy of central serous retinopathy. I. A controlled clinical study. II. Factors affecting prognosis. Trans Am Acad Ophthalmol Otolaryngol (1974) 0.79
Effect of tolbutamide and phenformin on lipolysis in adipose tissue in vitro. Am J Physiol (1966) 0.78
Physiologic determinants of serum urate levels in adolescence. Pediatrics (1979) 0.78
Light coagulation in presumed histoplasmic choroiditis. Controlled clinical study. Arch Ophthalmol (1971) 0.78
Effects of CV-3988, an antagonist of platelet-activating factor (PAF), on washed rabbit platelets. Thromb Res (1986) 0.77
Gait characteristics of the rheumatoid knee. Arch Surg (1972) 0.77
A prospective longitudinal study of neuropsychological and psychosocial factors in asymptomatic individuals at risk for HTLV-III/LAV infection in a methadone program: preliminary findings. Int J Neurosci (1987) 0.76
Simplified computation of confidence intervals for relative potencies using Fieller's theorem. J Pharm Sci (1966) 0.76
A teaching format in clinical pharmacology. Comparison of two xanthines and a placebo. J Clin Pharmacol New Drugs (1973) 0.76
Pharmacologic characterization of the rabbit neutrophil receptor for platelet-activating factor. Proc Soc Exp Biol Med (1990) 0.76
Criteria for subtyping poor prognosis schizophrenia: a numerical model for differentiating paranoid from non-paranoid schizophrenia. J Psychiatr Res (1974) 0.75
Respiratory hypersensitivity to Ascaris extract in guinea pigs sensitized by aerosol. Int Arch Allergy Appl Immunol (1980) 0.75
Population Increase of Pratylenchus hexincisus on Corn as Related to Soil Temperature and Type. J Nematol (1980) 0.75
On estimating relative potency from quadratic log-dose response relationships. Biometrics (1972) 0.75
An extract of rat submandibular glands activates platelets and enhances cutaneous vascular permeability in rats and guinea pigs. Life Sci (1986) 0.75
A new role for the pharmacist in the detection and evaluation of adverse drug reactions. Am J Hosp Pharm (1971) 0.75
Histopathology of lung cancers among smokers and nonsmokers in Florida. Int J Epidemiol (1990) 0.75
A novel platelet-activating protein derived from rat submandibular glands. Thromb Res (1985) 0.75
Interval estimates for the ratio of the means of two normal populations with variances related to the means. Biometrics (1985) 0.75
Statistical properties of normal distribution. JAMA (1969) 0.75
Selective antagonism of platelet-activating factor (PAF)-induced aggregation and secretion in washed rabbit platelets by CV-3988, L-652731, triazolam and alprazolam. Thromb Res (1987) 0.75
Comparison of reactions of human antisera in the methylene blue dye test for toxoplasmosis using bioassay procedures. Exp Parasitol (1967) 0.75
Use habits among adults of cigarettes, coffee, aspirin, and sleeping pills. Vital Health Stat 10 (1979) 0.75
Evaluation of the accuracy of on-site multi-analyte drug testing devices in the determination of the prevalence of illicit drugs in drivers. J Forensic Sci (1998) 0.75
Studies of the paw test and tumor-associated immunosuppression in mice. Int Arch Allergy Appl Immunol (1978) 0.75
Statistics in medicine. Ann Intern Med (1969) 0.75
Toward the use of surgical placebo-controlled trials. Transplant Proc (1997) 0.75
Bronchodilator testing "confidence intervals" based on the level of bronchial responsiveness. Chest (1992) 0.75
Advantages of a unit dose drug distribution system in surveillance of adverse drug reactions. Clin Toxicol (1972) 0.75
Activation of washed chicken thrombocytes by 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycero-3-phosphorylcholine (platelet-activating factor). Comp Biochem Physiol A Comp Physiol (1985) 0.75